RNAi-Mediated Downregulation of FKBP14 Suppresses the Growth of Human Ovarian Cancer Cells
Open accessAbstract
FKBP14 belongs to the family of FK506-binding proteins (FKBPs). Altered expression of FKBPs has been reported in several malignancies. This study aimed to reveal the expression profile of FKBP14 in ovarian cancer and evaluate whether FKBP14 is a molecular target for cancer therapy. We found that the FKBP14 mRNA level was significantly higher in ovarian cancer tissues than in normal tissues. FKBP14 expression was then knocked down in two ovarian cancer cell lines, SKOV3 and HO8910 cells, by a lentiviral short hairpin RNA (shRNA) delivery system. Reduced expression of FKBP14 markedly impaired the proliferative ability of ovarian cancer cells. Additionally, ovarian cancer cells infected with FKBP14 shRNA lentivirus tended to arrest in the G 0/G 1 phase and undergo apoptosis. Moreover, knockdown of FKBP14 induced cell apoptosis via increasing the ratio of Bax to Bcl-2. These results indicated that FKBP14 might be a diagnostic marker for ovarian cancer and could be a potential molecular target for the therapy of ovarian cancer.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
An anti-apoptotic role of FKBP22, favoring cell proliferation, by the over-expression of Bcl-2 and the silencing of caspases has been reported; conversely, shRNA-mediated FKBP14 inhibition induces cell cycle arrest and apoptosis.
“Recently, an anti-apoptotic role of FKBP22, favoring cell proliferation, by the over-expression of Bcl-2 and the silencing of caspases has been reported. Conversely, the shRNA-mediated FKBP14 inhibition induces cell cycle arrest and apoptosis [69]”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Emerging roles of caspase-3 in apoptosis
Porter, A. G., & Jänicke, R. U. (1999) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4400476 · Cited by 3,870 · see citing works
Role of Bcl-2 family proteins and caspases in the regulation of apoptosis
Ola, M. S., Nawaz, M. I., & Ahsan, H. (2011) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-010-0709-x · Cited by 916 · see citing works
FKBP Family Proteins: Immunophilins with Versatile Biological Functions
Kang, C., Ye, H., Dhe‐Paganon, S., & Yoon, H. S. (2008) · Neurosignals · doi:10.1159/000123041 · Cited by 331 · see citing works
Inherent calcineurin inhibitor FKBP38 targets Bcl-2 to mitochondria and inhibits apoptosis
Shirane, M., & Nakayama, K. I. (2002) · Nature Cell Biology · doi:10.1038/ncb894 · Cited by 319 · see citing works
Therapeutic strategies in epithelial ovarian cancer
Kim, A., Ueda, Y., Naka, T., & Enomoto, T. (2012) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-31-14 · Cited by 315 · see citing works
Immunophilins: for the love of proteins
Barik, S. (2006) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-006-6215-3 · Cited by 210 · see citing works
Baumann, M., Giunta, C., Krabichler, B., Rüschendorf, F., Zoppi, N., Colombi, M., Bittner, R. E., Quijano-Roy, S., Muntoni, F., Cirak, S., et al. (2012) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2011.12.004 · Cited by 162 · see citing works
FKBP12, the 12-kDa FK506-binding protein, is a physiologic regulator of the cell cycle
Aghdasi, B., Ye, K., Resnick, A. C., Huang, A., Ha, H. C., Guo, X., Dawson, T. M., Dawson, V. L., & Snyder, S. H. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.041614198 · Cited by 147 · see citing works
Sood, S., Chelu, M. G., van Oort, R. J., Skapura, D. G., Santonastasi, M., Dobrev, D., & Wehrens, X. H. T. (2008) · Heart Rhythm · doi:10.1016/j.hrthm.2008.03.030 · Cited by 132 · see citing works
Identification and validation of novel androgen-regulated genes in prostate cancer
Velasco, A. M., Gillis, K. A., Li, Y., Brown, E. L., Sadler, T. M., Achilleos, M., Greenberger, L. M., Frost, P., Bai, W., & Zhang, Y. (2004) · Endocrinology · doi:10.1210/en.2004-0311 · Cited by 131 · cited 1× · see citing works
“FKBP5 was overexpressed in prostate cancer (14), melanoma (15), and glioma (16).”
Role of FK506-binding protein 51 in the control of apoptosis of irradiated melanoma cells
Romano, S., D'Angelillo, A., Pacelli, R., Staibano, S., Luna, E. D., Bisogni, R., Eskelinen, E., Mascolo, M., Calı̀, G., Arra, C., et al. (2009) · Cell Death and Differentiation · doi:10.1038/cdd.2009.115 · Cited by 125 · see citing works
Jiang, W., Cazacu, S., Xiang, C., Zenklusen, J. C., Fine, H. A., Berens, M., Armstrong, B., Brodie, C., & Mikkelsen, T. (2008) · Neoplasia · doi:10.1593/neo.07929 · Cited by 88 · see citing works
Early versus delayed treatment of relapsed ovarian cancer
Rustin, G. J. S., van der Burg, M., Griffin, C. L., Qian, W., & Swart, A. M. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60126-8 · Cited by 70 · see citing works
Molecular predictors of response and outcome in ovarian cancer
Canevari, S., Gariboldi, M., Reid, J. F., Bongarzone, I., & Pierotti, M. A. (2006) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2006.03.003 · Cited by 44 · see citing works
Quinn, M. C. J., Wojnarowicz, P. M., Pickett, A., Provencher, D. M., Mes‐Masson, A., Davis, E. C., & Tonin, P. N. (2013) · International Journal of Oncology · doi:10.3892/ijo.2013.1797 · Cited by 32 · see citing works
Liu, Y., Li, C., Xing, Z., Yuan, X., Wu, Y. C., Xu, M., Tu, K., Li, Q., Wu, C., Zhao, M., et al. (2010) · FEBS Journal · doi:10.1111/j.1742-4658.2010.07795.x · Cited by 31 · see citing works
Identification of FKBP11 as a biomarker for hepatocellular carcinoma.
Lin, I.-Y., Yen, C., Liao, Y., Lin, S., Ma, H., Chan, Y., & Chen, Y. A. (2013) · PubMed · Cited by 25 · see citing works
Murray, M. L., Yang, M., Fauth, C., & Byers, P. H. (2014) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.36492 · Cited by 24 · see citing works
FKBP14is an essential gene that regulates Presenilin protein levels and Notch signaling inDrosophila
van de Hoef, D. L., Bonner, J. M., & Boulianne, G. L. (2013) · Development · doi:10.1242/dev.081356 · Cited by 23 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Chiarelli, N., Carini, G., Zoppi, N., Ritelli, M., & Colombi, M. (2018) · PLOS ONE · doi:10.1371/journal.pone.0191220 · Cited by 45 · see citing works
Zoppi, N., Chiarelli, N., Ritelli, M., & Colombi, M. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19040982 · Cited by 37 · see citing works
Role of Hydroxysteroid Dehydrogenase-Like 2 (HSDL2) in Human Ovarian Cancer
Sun, Q., Zhang, Y., Su, J., Li, T., & Jiang, Y. (2018) · Medical Science Monitor · doi:10.12659/msm.909418 · Cited by 28 · see citing works
Garrido, M. F., Martin, N. J.-P., Bertrand, M., Gaudin, C., Commo, F., Kalaany, N. E., Nakouzi, N. A., Fazli, L., Nery, E. D., Camonis, J., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0704 · Cited by 21 · see citing works
Exploiting convergent phenotypes to derive a pan-cancer cisplatin response gene expression signature
Scarborough, J. A., Eschrich, S. A., Torres-Roca, J., Dhawan, A., & Scott, J. G. (2023) · npj Precision Oncology · doi:10.1038/s41698-023-00375-y · Cited by 14 · see citing works
“Furthermore, many of the genes have been denoted as possible therapeutic targets in a variety of epithelial-based cancers, such as CDC7 in oral squamous carcinoma 30 and liver cancer 31 , ATP1B3 in gastric cancer 32 , and FKBP14 in ovarian cancer 33 .”
Penetrating Exploration of Prognostic Correlations of the FKBP Gene Family with Lung Adenocarcinoma
Wang, C., Shen, W., Anuraga, G., Hsieh, Y.-H., Ta, H. D. K., Xuan, D. V., Shen, C.-F., Wang, C., & Wang, C. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm13010049 · Cited by 14 · see citing works
Biological Characteristics and Carrier Functions of Pegylated Manganese Zinc Ferrite Nanoparticles
Guo, T., Dou, F., Lin, M., Huang, J., Zhou, C., Zhang, J., Yu, H., Jiang, X., Ye, J., Shi, Y., et al. (2019) · Journal of Nanomaterials · doi:10.1155/2019/6854710 · Cited by 11 · see citing works
Self-citationYang, L., Zhang, R., Yang, J., Bi, T., & Zhou, S. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s222555 · Cited by 8 · see citing works
Prognostic Significance of FKBP14 in Gastric Cancer
Ghoorun, R. A., Wu, X., Chen, H., Ren, D., & Wu, X. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s221943 · Cited by 8 · see citing works
Bai, Y., Li, L., & Zhang, Z. (2022) · Cell Cycle · doi:10.1080/15384101.2022.2097824 · Cited by 5 · see citing works
Wu, Z., Wei, Y.-J., Li, T., Zheng, J., Liu, Y.-F., & Han, M. (2024) · World Journal of Clinical Cases · doi:10.12998/wjcc.v12.i4.700 · Cited by 4 · see citing works
Александровна, Б. Э., Burdennyy, A. M., Урошлев, Л. А., Zaichenko, D. M., Филиппова, Е. А., Сергеевна, Л. С., Валерьевна, П. И., Astafeva, I., Fridman, M. V., Kazubskaya, T. P., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252111843 · Cited by 3 · see citing works
Exploiting convergent evolution to derive a pan-cancer cisplatin response gene expression signaturePreprint
Scarborough, J. A., Eschrich, S. A., Torres–Roca, J. F., Dhawan, A., & Scott, J. G. (2021) · medRxiv · doi:10.1101/2021.11.10.21265799 · Cited by 1 · see citing works
A new prognostic signature based on cancer associated fibroblast-driven genes in breast cancerPreprint
Wu, Z., Wei, Y., Liu, Y., Zheng, J., Yan, W., Liu, J., Han, M., & Li, T. (2023) · Research Square · doi:10.21203/rs.3.rs-2740940/v1
- Authors
- Lu, M., Miao, Y., Qi, L., Bai, M., Zhang, J., & Feng, Y.
- Affiliations
- Department of Obstetrics and Gynecology, Shanghai General Hospital of Nanjing Medical University, Shanghai, China
- Shanghai First People's Hospital (CN)
- Venue
- Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics
- Publisher
- Tech Science Press
- Published
- 2016-05-02
- Volume
- 23
- Issue
- 6
- Pages
- 267-274
- ISSN
- 0965-0407 (ISSN-L)
- PMC
- PMC7838629
- OpenAlex
- W2336264521
- Cited by
- 15
- References
- 18
- Citations by year
- 2024: 3 · 2023: 2 · 2022: 2 · 2021: 1 · 2019: 3 · 2018: 4
- FWCI
- 3.10
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Ovarian cancer diagnosis and treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Signaling Pathways in Disease
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Keywords
- FKBP, ovarian cancer, RNA interference, gene knockdown, cell proliferation, cell cycle arrest, apoptosis, Bax/Bcl-2 ratio, diagnostic biomarkers, therapeutic target, SKOV3 cells, HO-8910 cells
- MeSH terms
- Adult, Aged, Female, Humans, Middle Aged, Neoplasm Staging, Ovarian Neoplasms, Down-Regulation, Gene Expression, Gene Expression Regulation, Neoplastic, Apoptosis, Peptidylprolyl Isomerase, RNA Interference, Cell Line, Tumor, Cell Proliferation, Apoptosis Regulatory Proteins, G1 Phase Cell Cycle Checkpoints, Neoplasm Grading
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
